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Abstract
To test, whether 10 genes, diagnostic of renal allograft rejection in blood, are able to diagnose and predict cardiac allograft
rejection, we analyzed 250 blood samples from heart transplant recipients with and without acute rejection (AR) and with
cytomegalovirus (CMV) infection by QPCR. A QPCR-based logistic regression model was built on 5 of these 10 genes (AR
threshold composite score.37%=AR) and tested for AR prediction in an independent set of 109 samples, where it correctly
diagnosed AR with 89% accuracy, with no misclassifications for AR ISHLT grade 1b. CMV infection did not confound the AR
score. The genes correctly diagnosed AR in a blood sample within 6 months prior to biopsy diagnosis with 80% sensitivity
and untreated grade 1b AR episodes had persistently elevated scores until 6 months after biopsy diagnosis. The gene score
was also correlated with presence or absence of cardiac allograft vasculopathy (CAV) irrespective of rejection grade. In
conclusion, there is a common transcriptional axis of immunological trafficking in peripheral blood in both renal and cardiac
organ transplant rejection, across a diverse recipient age range. A common gene signature, initially identified in the setting
of renal transplant rejection, can be utilized serially after cardiac transplantation, to diagnose and predict biopsy confirmed
acute heart transplant rejection.
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Introduction
Despite improvements in immunosuppressive therapy over the
years, approximately 30–40% of heart transplant recipients
require treatment for acute rejection (AR) in the first year after
transplantation [1]. AR is a major risk factor for graft dysfunction,
mortality, and the development of cardiac allograft vasculopathy
(CAV) - the main cause of late graft failure [2]. Thus, methods that
improve early diagnosis and treatment of AR are likely to reduce
morbidity and improve survival after heart transplantation.
Currently, the definitive diagnosis of allograft rejection relies on
the endomyocardial biopsy (EMB)—an expensive, invasive, and
inconvenient procedure. Most heart transplant recipients undergo
routine EMB procedures up to 15 times in the first year, and more
frequently if rejection is detected. This procedure however is
limited by sampling error and inter-observer variability [3,4].
Potential complications include arterial puncture, vasovagal
reactions and prolonged bleeding during catheter insertion,
arrhythmias and conduction abnormalities, pneumothorax, biop-
sy-induced tricuspid regurgitation, and even cardiac perforation
[5–7]. A noninvasive biomarker panel for cardiac AR that allows
frequent immunologic monitoring of the graft would be of
considerable value [8,9], and the diagnosis of AR prior to
development of histopathological changes would enable the
optimization of immunosuppressive therapy to prevent progres-
sion to chronic allograft dysfunction [10]. Recently our group has
found a highly sensitive and specific gene-based biomarker panel
for diagnosis and prediction of biopsy confirmed acute renal
transplant rejection [11], which was independently validated in a
randomized multicenter trial [12,13]. In the previous study, we
conducted extensive microarray discovery and QPCR validation
studies on 489 unique peripheral blood samples from pediatric
kidney transplant recipients, with and without biopsy proven AR.
Correlation studies of gene expression profiles in peripheral blood
samples of pediatric and young adult renal transplant patients with
biopsy-proven acute rejection identified a highly regulated set of
10 genes by microarray analysis (CFLAR, DUSP1, IFNGR1,
ITGAX, PBEF1, PSEN1, RNF130, RYBP, MAPK9, and
NKTR), which was subsequently validated by QPCR, and which
by logistic regression analysis yielded a probability score for non-
invasive diagnosis of biopsy confirmed renal AR in pediatric and
young adult patients [11].
Recent studies indicate that there likely is a common
immunological mechanism for AR across different solid organ
transplants [14–17]. We could define serum proteins highly
increased in renal AR that were also increased during cardiac and
liver AR [15]. The purpose of this study was to assess if the same
peripheral blood gene panel discovered as pertinent for diagnosis
of renal transplant rejection can also diagnose and predict heart
transplant rejection in peripheral blood. We developed a 5-gene
logistic regression model from our previously published 10-gene
renal AR signature [11], that diagnosed acute cardiac allograft
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rejection in patient blood with 89% accuracy and predicted
cardiac AR within 6 months prior to diagnosis by cardiac biopsy,
with 80% sensitivity.
Methods
Study Design
The present study design is summarized in Figure 1 and
described here: We previously conducted extensive cross-platform
microarray discovery and QPCR validation studies on 489 unique
peripheral blood samples from pediatric kidney transplant
recipients with and without biopsy proven AR which led to the
definition of a blood QPCR 10-gene signature (CFLAR, DUSP1,
IFNGR1, ITGAX, PBEF1, PSEN1, RNF130, RYBP, MAPK9,
and NKTR) for renal AR which by logistic regression yielded an
AUC of 93.7% for diagnosis of AR using 5-genes (CFLAR,
DUSP1, PBEF1, MAPK9, RNF130) in independent samples from
a randomized multi-center trial (Figure 1A).
To investigate, whether the same 10-gene signature may also be
modulated in cardiac AR, we investigated 141 peripheral blood
samples with matched EMB, from adult heart transplant recipients
by QPCR (Figure 1B). Firstly, we randomly assigned 32 samples
into training (2/3) and test (1/3) sets for rejection and stable
phenotypes; given the current clinical practice in most heart
transplant centers of only treating Grade 3 AR, we included only
rejection with Grade 3 in this QPCR discovery set. A multinomial
logistic regression model using 5 genes, built in the training-set and
validated in the test-set was secondly applied to an independent
QPCR validation set of 86 blood samples with matched EMB.
The model was tested (1) for its ability to segregate samples with
AR from those without any evidence of rejection; it was tested (2)
for its ability to discriminate AR from acute CMV infection in 12
blood samples from patients with documented active CMV
infection; and the model was tested (3) for its ability to predict
the development of CAV at 2- and 4-years post transplantation in
patients with biopsy proven AR at 1 year, as AR is an important
risk factor for the development of CAV. Finally, serial blood
samples were available from 23 patients that were drawn within 6
months prior to or after an episode of biopsy-confirmed AR. The 5
gene model was tested in this QPCR prediction-set to ascertain the
‘‘rejection score’’, to determine whether the gene expression score
rose prior to episodes of biopsy-proven AR, and whether the score
declined after treatment of the rejection event.
Figure 1. Study Design: A peripheral blood 10-gene panel for Solid Organ Transplant Rejection. A. The process of microarray discovery
and QPCR validation of a 10 gene panel in 489 peripheral blood samples from pediatric and young adult renal transplant recipients, with validation of
the gene biomarker panel in a prospective, randomized, multicenter trial (AUC= 0.937). B. The 10 genes were tested by QPCR in 141 peripheral blood
samples from adult cardiac transplant recipients. A minimal logistic regression model of 5 genes was used for independent prediction for AR
diagnosis in 86 samples and AR prediction prior to biopsy diagnosis.
doi:10.1371/journal.pone.0082153.g001
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Study Population
Ethics Statement. All patients involved in this study
provided informed consent to the study protocol approved by
the institutional (Stanford University) review board for studies in
human subjects.
Sample Selection. This biomarker study utilized a cohort of
45 consecutive patients undergoing first heart transplantation
between January 2002 and May 2005 at Stanford University. This
cohort was a selected subset of samples from a clinical trial that
was funded by the National Institutes of Health (Program Project
Grant (PPG) 5P01AI050153-02) and had been assembled
prospectively to study the relationship between CMV infection
and the development of CAV. Exclusion criteria for this trial
included age ,10 years, renal dysfunction requiring prolonged
dialysis, and inability or unwillingness to provide signed informed
consent. Study patients in this trial had been monitored for acute
cellular rejection by surveillance EMB performed at the following
scheduled intervals after transplant: weekly during the 1st month,
biweekly until the 3rd month, monthly until the 6th month, and
then at months 9 and 12. Biopsies were graded according to the
1990 International Society for Heart and Lung Transplantation
(ISHLT) classification system as 0, 1A, 1B, 2, 3A, and 3B (Table 1)
[18]. Though there was a large pool of samples in the original
clinical trial (PPG 5P01AI050153-02), a modest number of
samples could not be used as not all samples had adequate RNA
remaining after conduct of the CMV studies from the original
grant, some were currently being utilized as part of concomitant
ongoing studies by HV, and samples were not selected if the
amount of remaining RNA in the archive was ,500 ng. In
addition, to maintain strict quality controls for the QPCR
experiments, only those samples were selected that had excellent
quality RNA (RIN.5). Final sample selection for this study used
all remaining samples and then further sub-selected samples that
met the following clinical phenotypes: (1) acute rejection, CMV2
(acute rejection or AR group); no rejection, CMV2 (stable or STA
group); no rejection, CMV+ (CMV group); (2) AR blood samples
were required to be drawn on the same day of the biopsy, just
prior to the biopsy procedure and prior to any treatment
intensification for AR; (3) STA patients selected were demograph-
ically matched with the identified AR patients. In addition, (4) for
all selected AR samples, we pulled all available samples paired
with these rejection episodes within a 6 month time frame prior to
(pre-) and after (post-) the rejection episode. The rationale for this
aspect of sample selection before and after AR was based on our
previous study on kidney transplant rejection that suggested that
the rejection gene signature in kidney transplantation could
identify pre-acute rejection samples within a 6 month time-frame
prior to AR [11–13]. (5) Multiple samples from a single patient
were utilized as long as they had a matched biopsy with conclusive
phenotypic diagnosis of AR or STA, with the caveat that the STA
sample had to be .1 year distant from the AR episode, so that
there was no overlap between STA and pre- and post-AR samples
which were only collected within the 6 month timeframe of AR.
This resulted in a final selection of a total of 141 unique blood
samples selected from 45 unique adult heart transplant recipients.
The breakdown of the different blood sample categorizations were
as follows: 40 samples were selected where the EMB showed no
evidence of cellular rejection (Grade 0), 31 samples were selected
where the EMB was classified as Grade 1A, 22 samples were
selected where the EMB was classified as Grade 1B, only 2 samples
were available when the EMB was classified as Grade 2, and 11
samples were selected where the EMB was classified as
Grade$3A. All available Grades of AR meeting our selection
criteria were selected for this analysis. In addition, 12 blood
samples were selected as they had been drawn during episodes of
CMV reactivation (defined as .100 copies of CMV DNA
amplified from peripheral blood mononuclear cells), and 23
samples were drawn within 6 months prior to (n = 11), or after an
episode of cellular rejection (n= 12). For the purposes of this study,
stable (STA) was defined as the EMB showing no evidence of
lymphocytic infiltrate (Grade 0), while acute rejection (AR) was
defined as EMB showing evidence of mild-severe lymphocytic
infiltrate (Grade 1A–3B).
In the study, yearly coronary angiograms were performed with
intravascular ultrasound (IVUS), enabling highly accurate mea-
surements of vessel wall thickness, for assessment of CAV which is
characterized by diffuse intimal thickening of the graft coronary
arteries [19]. All study participants were assigned a CAV score
from 0–4: 0= no evidence of CAV by angiography or IVUS;
1 = coronary artery intimal thickening by IVUS without angio-
graphic disease; 2 = coronary artery stenosis,30% by angiogra-
phy; 3= coronary artery stenosis of 30–70% by angiography;
4 = coronary artery stenosis.70% by angiography or placement of
an intra-coronary stent.
Peripheral whole blood samples were collected and stored at the
following time-points post-transplant in the parent PPG: day 14;
months 1, 2, 3, 4, 5, 6, 9, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52,
56, and 60. For demographic characteristics of patients included in
the study refer to Table 2.
Patient Immunosuppression Protocol. Post-transplant im-
munosuppression consisted of Daclizumab (1 mg/kg IV) admin-
istered at the time of transplant surgery and on alternate weeks for
a total of five doses, Cyclosporine (3–5 mg/kg/day); Prednisone
initiated at 1 mg/kg/day and tapered to ,0.1 mg/kg/day by the
6th post-operative month; and either Mycophenolate mofetil
1000–3000 mg daily, or Sirolimus 1–4 mg daily. Changes to this
standard immunosuppressive regimen were made on an individual
basis. All patients in whom either donor or recipient was CMV
antibody positive received standard CMV prophylaxis consisting
of 4 weeks of intravenous Ganciclovir. Those recipients who were
CMV antibody negative and received a heart from a CMV
antibody positive donor received an additional 3 months course of
CMV hyperimmune serum and up to 80 days of Valganciclovir.
Sample Collection, Total RNA Extraction and Quantitative
Real-time PCR (QPCR)
Peripheral blood (2.5 mL) was collected into PAXgeneTM Blood
RNA tube (PreAnalytiX/Qiagen, Valencia, CA, USA) containing
lysis buffer and RNA stabilizing solution. Total RNA was
extracted with the PAXgeneTM Blood RNA System (PreAnaly-
tix/Qiagen, Valencia, CA, USA) following the manufacturer’s
instructions and as previously published [11], yielding a final
concentration of 50–300 ng/ml. A total of 500 ng RNA were
reverse transcribed in a 20 ml reaction using the RT2 First Strand
cDNA Synthesis Kit (Bioscience), followed by quantitative real-
time polymerase chain reaction (QPCR) in 384-well plates using
the QPCR Master Mix (RT2 SYBR Green/ROX) (Bioscience).
5 ng cDNA were added to each 10 ml QPCR reaction in
duplicated wells. QPCR reactions were run on the ABI PRISM
7900HT Sequence Detection System (Applied Biosystems, Life
Technologies, Foster City, CA). The relative amount of RNA
expression was calculated using comparative CT method [20] with
ribosomal 18S RNA as endogenous control gene and universal
RNA as reference sample (Human Universal RNA, Stratagene,
Agilent Technologies, Santa Clara, CA). Additionally, FOXP3 a
previously reported AR biomarker, was included in each plate to
serve as a positive control gene.
Blood Gene Panels for Renal and Cardiac Rejection
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Selection of 10 genes for QPCR in heart transplantation
Selection of the 10 genes for gene expression analysis in this
study was done through a multi-platform microarray discovery
followed by QPCR validation in kidney transplantation [11].
Among 10,412 common genes probed on all the platforms
analyzed 32 genes were selected based on FDR of ,5% for
differential expression in AR and biological relevance to the
immune response; this resulted in a selection of 32 genes [11].
QPCR validation on an independent set of samples resulted in 10
genes significantly differentially expressed between rejection and
stable graft groups which were subsequently used for building a
classification model by logistic regression [11]. In the present
study, the same set of 10 genes (CFLAR, DUSP1, IFNGR1,
ITGAX, PBEF1, PSEN1, RNF130, RYBP, MAPK9, and NKTR)
was investigated in heart transplant blood samples by QPCR.
Statistical Analysis
Mean 6 standard deviations of were calculated for patient
demographic variables, and mean 6 standard errors of means
were determined for QPCR results. Student T-tests, Chi-square
tests, Hypergeometric tests [21,22], Spearman-, Pearson-, or
Kendall- correlation coefficients, and logistic regression models
were calculated using Statistical Analysis Software (SAS) Version
v9.2 (SAS Institute Inc., NC) and R version 2.15. A 5-gene logistic
regression model was built on the categorical variables AR versus
STA using relative gene expression values. The model was built in
SAS 9v.2 and reproduced in R 2.15, with likelihood p-
value = 0.008. P-values were two-sided, and those #0.05 were
considered significant in all statistical tests. We used Pearson
correlation coefficients to evaluate the potential association
between continuous variables and gene expression of the 5 genes
from QPCR and used T-tests to evaluate gene expression levels for
the categorical variables, such as recipient and donor gender. We
determined whether a high peripheral gene-based prediction score
for cardiac AR predicted the subsequent development of CAV by
calculating Spearman correlation coefficients between the gene-
based probability scores for AR and subsequent CAV scores. We
used the hypergeometric test [21] to determine whether the
proportion of the highly expressed genes in each cell type was
statistically significant or not. The p-values from hypergeometric
tests were corrected for multiple hypotheses using Benjamini–
Hochberg correction [22].
Results
5 genes diagnosed Acute Cellular Rejection after Heart
Transplantation in Blood
QPCR-generated gene expression data for a set of 10 genes
(CFLAR, DUSP1, IFNGR1, ITGAX, PBEF1, PSEN1, RNF130,
RYBP, MAPK9, and NKTR), originally identified and validated
in 458 peripheral blood samples from pediatric recipients of a
renal transplant [11], were cross-validated in peripheral blood
samples from 141 heart transplant recipients and demonstrated
significant differences between rejection and non-rejection groups.
Using only rejection with Grade 3 in the discovery set and by
randomly assigning STA samples, a logistic regression model was
built in the 1/3 training-set alone to predict AR in the
independent 2–3 validation-set set. Using a multinomial logistic
regression model, a minimum set of 5 genes was identified that
could accurately classify acute rejection blood samples from
Table 1. 1990 ISHLT Standardized Cardiac Biopsy Grading Scheme for Acute Cellular Rejection and Corresponding Number of
Samples Studied [18].
Grade N=141 Histological features
0 75 (40+23*+12**) No rejection
1, mild 53
A- Focal 31 Focal perivascular and/or interstitial infiltrate without myocyte damage
B- Diffuse 22 Diffuse infiltrate without myocyte damage
2, moderate (focal) 2 One focus of infiltrate with associated myocyte damage
3, moderate 11
A-Focal 7 Multifocal infiltrate with myocyte damage
B- Diffuse 4 Diffuse infiltrate with myocyte damage
*23 samples drawn within 6 months prior to or after episodes of acute rejection
**12 samples drawn from patients with CMV infection (.100 copies of CMV DNA amplified from peripheral blood mononuclear cells).
doi:10.1371/journal.pone.0082153.t001
Table 2. Clinical profile of 45 study patients.
Patient Clinical Variables
Age (years, mean 6 SD) 48.2617.3
Sex (% male) 73%
Race/ethnicity, n (%)
Caucasian 36 (80%)
-Asian 1 (2%)
-Hispanic 4 (9%)
-African-American 3 (7%)
-Other 1 (2%)
Primary disease, n (%)
-Ischemic CM 16 (36%)
-Dilated CM 58%)
-Other 3 (7%)
Diabetes, n (%) 13 (29%)
Hypertension, n (%) 45 (100%)
History of Smoking, n (%) 7 (16%)
Sample time (mean 6 SD) [months post Txp.] 15.0610.9
doi:10.1371/journal.pone.0082153.t002
Blood Gene Panels for Renal and Cardiac Rejection
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samples without acute rejection (stable, STA) with a median
accuracy of 0.73. The model from the published kidney 5 genes
(DUSP1, MAPK9, NKTR, PBEF1, and PSEN1) did not achieve
better performance than the best subset of the 5 genes selected in
the heart data-set (DUSP1, IFNGR1, MAPK9, PBEF1, and
RYBP) which had with a chi-square score of 9.57. Chi-square
score for logistic regression models built using the 10 genes showed
that in the data-set used, using 5 gene models had the same
performance as models using six or more genes (Chi-square of the
5 genes and 10 genes are 9.57 vs. 9.79 respectively). Based on the
Receiver Operating Characteristic (ROC) curve with an AUC of
0.89 (Figure 2A), the cutoff for the predicted probability for a
sample to be classified as AR (Theta = h) was h=0.37 which had
the best sensitivity and specificity by maximizing the correct rate,
to discriminate between AR and STA. In the logistic regression,
each of the 5 regression coefficients describes the size of the
contribution of that gene as a risk factor for diagnosing AR, where
the larger the coefficient, the greater the influence of that gene in
AR. A positive coefficient suggests that the explanatory variable
increases the probability of AR where as a negative coefficient
decreases the probability of AR.
The fixed 5 gene-model was subsequently tested in 86
independent samples with varying AR grades, STA and CMV
diagnoses, and identified AR samples of all grades ,3 with 89%
accuracy (87% sensitivity, 90% specificity is, 94% PPV, 80%
NPV; Figure 2A, misclassified samples in 2A are indicated by an
asterix; Table 3 shows individual prediction scores for the different
AR grades). The sensitivity for prediction of AR was highest for
samples with ISHLT biopsy Grade 1B (100%), and was 82% for
prediction of Grades 3A/B and 81% for Grade 1A. Sensitivity for
prediction of ISHLT Grade 2 events was not calculated as there
were only 2 samples in this category and both classified correctly.
The 5-gene prediction score could not segregate samples with
paired biopsies with fibrosis (Grade 3B; p= 0.21) and myocyte
damage (Grades 3A and 3B; p= 0.07) from those with lesser
grades of AR (Grades#2). The prediction probability of the 5-
gene model was highest in blood samples from Grade 1B rejection
(Grade 1B vs. Grade 1A; p= 0.01; Grade 1B vs. Grade 3A/B,
p= 0.01), which allows to hypothesize that the signal for the 5-
gene expression profile, likely comes from trafficking mononuclear
cells in blood, as previously suggested in renal rejection [11,23],
and reflects the extent of the inflammatory response in the graft,
which is known to be greatest in Grade 1B AR (Figure 2B).
The 5-gene model discriminated AR from active CMV
All 12 CMV-positive samples were correctly predicted to have
no AR, suggesting that there is no concern for innate immune
activation in CMV confounding the 5-gene expression panel for
AR in blood.
The 5-gene AR Prediction Score was significantly
associated with development of CAV
As cardiac AR is a known important risk factor for the
development of CAV the second most common cause of death,
early prediction of CAV in patients with AR would be of great
value. In this regard, we investigated whether our 5-gene model
was associated with the development of CAV in patients with AR.
There was a significant positive correlation between the probabil-
ity score for prediction of AR in a blood sample drawn at 1 year
post-transplantation, and the subsequent development of CAV in
that same patient at 2 years (r = 0.73, p = 0.02) and at 4 years
(r = 0.82, p = 0.01) post-transplantation. Furthermore, predicted
probabilities of AR at 1 year were significantly higher in patients
with higher grades of CAV (CAV score$3) vs. mild grades of
CAV (CAV score#2) at 4 years post-transplantation (99%61%
vs. 32%614%, p= 0.001), which indicated that patients with
higher predicted AR probability, independent of AR histology
grade, may be at greater risk to develop more severe CAV at
subsequent follow-up.
The 5-gene model was not confounded by demographic
or clinical variables
No significant demographic or clinical variables (including age,
sex, and time post-transplant) were found to be confounders for
the ability of the 5-gene model to diagnose AR (maximum
|r|,0.4 or p.0.05), and specifically time-post transplant for
sampling did not confound the score, which has been an issue in
other biomarker studies of this nature [3].
The 5-gene model predicted AR in blood prior to
histological diagnosis in EMB
The AR prediction score was measured on blood samples
drawn within a period of 6 months prior to a biopsy proven AR
event (grades 1A, 1B, or 2; Figure 1). As seen in Figures 2C and
2D, there was a statistically higher likelihood (p,0.0001) of a high
prediction score for AR (mean prediction score 80%; Figure 2D) in
the blood samples drawn prior to AR than a blood sample drawn
prior to a negative biopsy (mean prediction score 17%; Figure 2C).
The 5-gene probability score for AR in many blood samples
drawn within 1–6 months after treatment of acute rejection varied
between (0%–100%), with an average prediction score of 87%
(n= 12 samples; Figure 2D).
Discussion
We conducted the first study to cross-validate a gene expression
panel that detected acute rejection after kidney transplantation for
detection and prediction of acute rejection in heart transplant
recipients. Our 10-gene panel was differentially regulated in the
periphery at the time of histologically confirmed acute rejection
irrespective of tissue source. Additionally, these genes were
indicative of histological acute rejection in both children and
adults, as our study in renal AR [11] was performed in pediatric
and young adult renal allograft recipients and the present study in
cardiac AR was performed in adult heart transplant recipients. It
was possible to narrow the original 10-gene panel to an even
smaller set of 5-genes that were not confounded by clinical
variables, such as transplant recipient age and sex, time post-
transplant, or innate immune activation, discriminating AR from
concomitant CMV infection. The lack of any confounding effect
from active CMV infection suggested that the gene expression
signature reflects the identification of a specific alloimmune
trafficking response that is independent of the heightened innate
immune response seen in CMV infection.
This peripheral blood gene expression signature correlated with
the activation profile of the inflammatory infiltrate, rather than the
grade of rejection or the extent of fibrosis or myocyte damage. The
5-genes have been shown previously to be highly expressed in cells
of the monocyte and macrophage lineage [11,23], suggesting that
the gene expression panel is detecting trafficking of activated
monocyte lineage cells; cells that are common to the inflammatory
injury of acute rejection in kidney and heart transplantation.
Individual genes such as CD27, CD40, TIRC7, cytokines
(interferon-c, interleukin [IL]-2, IL-4, IL-6, IL-8), and cytotoxic
T-cell effector molecules (Perforin, Granzyme B, FasL) have been
previously found to be elevated in rejecting biopsy samples [24–
30] and peripheral in blood [31–33] at the time of cardiac allograft
rejection, but many of these are also regulated during infection
Blood Gene Panels for Renal and Cardiac Rejection
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Figure 2. Predicted Probability of AR in 141 Peripheral Blood samples from Adult Heart Transplant Recipients. A. The predicted
probability of a sample having a non-invasive diagnosis of AR, based on the logistic regression score on the 5-gene model is shown on the Y Axis
(score range 0–100%). A score.37%, from the model, classifies a sample as AR, a score,37% from the model classifies a sample as non-AR. The score
is shown on all 141 samples, inclusive of the training (n = 32; 11 Grade 3 AR, 21 STA) and the test set samples (12 CMV, 19 STA, 31 AR-Grade 1a, 22 AR-
Grade 1b, 2 AR Grade 2). The clinical sample phenotype is based on the matched biopsy histology read. The misclassified samples from the histology
read and the blood gene-model read are marked by asteryx. B. The Individual and group predicted probabilities for all 66 AR samples. The blood-
gene model classifies all AR-Grade 1b correctly (a significant finding with p = 0.01, for classification of other AR grades). C. The predicted probabilities
for AR for all Stable samples without any evidence of acute rejection (STA), with sampling times at different times post-transplantation. D. The
predicted probabilities for AR for all 55 untreated AR samples (AR-Grades#2), where no treatment intensification was given for the diagnosis of AR.
Serial samples from these patients collected within 1–6 months prior (n = 11), or within 1–6 months after (n = 12), these AR episodes. The gene-model
predicts AR prior to biopsy diagnosis and remains elevated in most samples without immunosuppression intensification.
doi:10.1371/journal.pone.0082153.g002
Table 3. Prediction Performance of the Gene-Model on Different Clinical Phenotypes (Biopsy Confirmed).
Prediction Sets AR (prediction) STA (prediction) Total
Sensitivity (AR) or Specificity
(Non-AR)
AR (N=55) 49 6 55 89% Sensitivity
-A (N = 31) 25 5 31 81% Sensitivity
-1B (N = 22) 22 0 22 100% Sensitivity
-2 (N = 2) 1 1 2 Not calculated
Non-AR (N=31) 3 28 31 90% Specificity
-STA (N= 19) 3 16 19 84% Specificity
-CMV+(N = 12) 0 12 12 100% Specificity
For all 86 samples in the prediction set, Sensitivity = 87%, Specificity = 90%.
AR: acute rejection (Grades 1–3); STA: stable (Grade 0).
doi:10.1371/journal.pone.0082153.t003
Blood Gene Panels for Renal and Cardiac Rejection
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and other causes of inflammation. Microarray technologies offer
the option of simultaneously screening thousands of novel
candidate genes in an unbiased fashion, while controlling for
multiple clinical confounders, enabling the identification of panels
of genes in peripheral blood that may be very sensitive and specific
for histological acute rejection [34,35] and provide more robust
performance than any single gene analysis [3,36]. The discovery of
the 10 gene-set in this study came from global gene expression
analysis of ,54,000 genes on different microarray platforms using
peripheral blood samples from pediatric kidney transplant
recipients [11] and this gene-panel was validated as highly
accurate for acute rejection diagnosis in a prospective, randomized
multicenter clinical trial. As the same genes were found to also
detect AR in adult heart transplant recipients in the present study,
the performance of this gene-set to detect biopsy confirmed AR in
different solid organs and across the span of gender, post-
transplant time, differences in immunosuppression, transplant
centers and recipient age, is highlighted and further supports the
presents of a common rejection specific immune axis.
The Cardiac Allograft Rejection Gene expression Observation-
al (CARGO) study [3], identified an 11-gene PCR classifier,
largely from the literature, that was subsequently commercialized
into the AlloMap Molecular Expression Test (XDx, Brisbane,
CA). This test provides a negative predictive value (NPV) of 99%
for moderate-severe cellular rejection by EMB, providing a means
for ruling-out the presence of rejection but has low positive
predictive value (PPV) and sensitivity for ruling-in the presence of
AR. The clinical utility of a blood gene profiling approach for
ruling out AR was demonstrated in a randomized study on 600
heart transplant recipients, where there was non-inferiority of an
Allomap-based rejection monitoring strategy, compared to EMB,
with respect to a composite endpoint of AR, graft failure and
death, and a reduction in the number of EMBs performed in this
study by almost 70%, consistent with the high NPV associated
with the Allomap test [37]. However, the PPV of 20–40% for the
Allomap test for ruling-in the presence of AR in the same study
suggested that complementary approaches for the diagnosis and
prediction of AR, such as the use of the present 5-gene panel by
this study, are needed.
Although management of heart transplant recipients often
varies between centers, most transplant programs only consider
rejection of Grade 3A or 3B (showing myocyte damage) as
clinically relevant, and therefore warranting treatment. Currently,
AR of grades of 1A, 1B and 2 are frequently dismissed, without
any additional treatment delivery, perhaps because these lower
histological grades of rejection are observed so commonly in the
protocol biopsies performed. Interestingly, the inflammatory
infiltrate that is common to all histological grades (1–4) of AR
and is singularly absent in the non-rejection biopsies (Grade 0),
suggests that the presence of an infiltrate is a very common finding,
and in the absence of myocyte damage its clinical relevance in
heart transplantation remains unclear. Nevertheless, the presence
of an inflammatory infiltrate of predominantly mononuclear cells
is the hallmark of AR in other solid organ transplants such as
kidney [38], lung [39] and small intestine [40], where the infiltrate
is believed to be pathologically and clinically relevant, and triggers
a treatment response of bolus immunosuppression. The ISHLT
1990 classification scheme for acute cardiac allograft rejection
distinguished 3 grades of mild-moderate cellular rejection: Grades
1A, 1B, and 2, based on absence (Grades 1A and 1B) or presence
of myocyte damage (Grade 2), and focal (Grade 1A) versus diffuse
(Grade 1B) nature of the lymphocytic infiltrate (Table 1).
Subsequent clinical investigations of these mild-moderate rejection
grades focused on their temporal occurrence, requirement for
therapy, and progression to more severe grades of rejection [41–
45], and ultimately led to a revision of the ISHLT classification
scheme in 2004, which included a single mild grade of rejection
(1R), which subsumed the original Grades 1A, 1B, and 2 [46].
The 5-gene model developed and tested in this study can
diagnose acute cardiac rejection of Grades 1A–3B (no Grade 4
samples were available for this study), with the highest confidence
for diagnosing Grade 1B rejection. Molecular subtyping has
demonstrated evidence of myocyte apoptosis in Grade 1B biopsies
that is a feature of myocyte damage typical of Grade 3A biopsies,
but not of less severe (Grade 1A) rejection [47]. Such data suggests
that Grade 1B biopsies may share molecular similarities with
Grades$3A, and that molecular approaches may provide novel
insights into tissue injury that may complement the light-
microscopic criteria traditionally used for biopsy grading. Bern-
stein et al [48] recently performed a post hoc analysis of the
CARGO data, specifically examining gene expression scores for
blood samples accompanying EMB of varying grades. They
demonstrated that the mean gene expression scores for Grades 1B
and $3A were indistinguishable, once again suggesting a potential
overlap along a molecular spectrum of rejection severity. A recent
study by Holweg et al. [49] profiled EMB of patients with different
cardiac transplant rejection grades. Although grade 1B was found
to be distinct from the clinically relevant AR grades 3A and 3B in
this study, all of these grades were found to share a number of
overlapping pathways consistent with common physiological
underpinnings. The mean gene expression score for Grade 1B
also suggested its molecular distinction from other Grades (1A and
2) classified as mild rejection in the 2004 revised grading scheme
[46]. Our results are consistent with those of Bernstein, and
suggest that combining Grades 1A, 1B, and 2 in the 2004 revised
grading scheme may undermine the independent value and
distinct inflammatory nature of different rejection grades. The
gene expression similarities identified here in grade 1B and grade 3
AR have the potential to revise the clinical perspective on acute
graft rejection, pending the results of additional prospective
studies.
The 5-gene model developed in this study could also predict the
onset of AR, months before EMB based histological diagnosis.
Importantly, the AR probability score defined by our 5-gene
model decreased again after augmented immunosuppressive
therapy in patients with rejection grades 3A/B, and remained
elevated in untreated cases of AR of grades#2. Further studies are
required to evaluate the prediction probability of this gene-set as a
means to titrate immunosuppression in heart transplantation,
without the need for frequent protocol biopsies.
Our previous work in kidney transplantation [11,23,34] has
highlighted the fact that the 10 selected genes in our original
model are highly expressed in cells of the monocyte lineage. The
statistical approach of deconvolution [23], now available as cell-
specific Significance Analysis of Microarrays or cSAM [50], also
demonstrated that the monocyte-specific signal in peripheral blood
[11,23] drives the differential expression of peripheral genes in
acute renal transplant rejection. As our previous studies in kidney
transplant rejection [23] have not identified any differences in the
numbers of circulating monocytes, the gene signature likely reflects
an activation status of this cell lineage, though additional work is
required to validate these findings as sorted monocytes were not
available for evaluation in this study. As this same gene set also
displayed differential regulation in all grades of acute heart
transplant rejection, our work likely highlights a novel, and
hitherto unrecognized role for the activated monocyte as the key
peripheral trafficking cell in acute rejection, both within the graft
and as a biomarker for acute rejection in the periphery. Our group
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is currently assessing the performance of the same gene set as a
non-invasive marker for AR in other solid organ transplants,
specifically lung and intestinal transplantation.
Although these results are intriguing, they mandate further
validation in larger, prospective cohorts, as the sample set in this
study was small and the analysis was retrospective in nature. The
gene panel demonstrated the utility of distinguishing the presence
of cellular rejection (graded from 1 to 3, or mild to severe) from
immunologic quiescence; however, further refinement of our
algorithm is planned to distinguish clinically-relevant grades of
rejection from those that do not require treatment. Additionally,
this study focused on the ability of our model to diagnose acute
cellular rejection, and not antibody-mediated (humoral) rejection,
as diagnostic assays for the presence of antibody-mediated
rejection were not routinely performed during the sample
collection period.
CAV, the leading cause of late morbidity and mortality after
heart transplantation, is a complex multifactorial process mediated
by both immune and non-immune factors. The diffuse nature of
CAV, which usually involves the entire coronary arterial tree [51]
suggests primarily an immune etiology. Prior observational studies
suggest that cellular AR and CAV are closely related processes
[52,53]. Our finding of a positive association between AR
prediction scores and subsequent development of CAV further
supports this theory. A similar finding was also noted by the an
association of the AlloMap with cardiac vasculopathy, as a higher
AlloMap score was found in 20 cardiac recipients with EMB
confirmed vasculopathy and compared to 49 control patients [54].
Thus our finding also supports that gene expression testing could
be used to determine a patient’s future risk of CAV—and could be
used to potentially tailor prophylactic strategies to prevent CAV
development. Additional validation of this work in larger cohorts is
warranted. The strong correlation seen for the AR prediction
score of the current 5-gene model with the development of
subsequent CAV suggested that this inflammatory infiltrate, even
independent of rejection grade and similar to its downstream effect
in other solid organs [11,36,37] may not be benign and likely
accelerates the evolution of chronic injury, and is therefore
potentially deserving of clinical vigilance and treatment.
In conclusion, an internally validated 5-gene classifier panel,
from a larger set of 10 genes, has been developed to non-invasively
screen for the presence of acute cellular rejection after heart
transplantation; the same 10 genes also being diagnostic of acute
kidney transplant rejection. The markers studied had a priori
plausibility, given their demonstrated utility for diagnosis of acute
rejection after kidney transplantation, reflecting common path-
ways of immune activation [17]. The high specificity and PPV of
the 5-gene panel in peripheral blood samples fulfill a critical unmet
need for AR monitoring in heart transplantation and warrant
additional validation. As mentioned previously, the currently-
available AlloMap test has very high NPV, and therefore enables
clinicians to rule out the presence of rejection. This assay, with a
high PPV, would therefore be complementary by concurrently
enabling clinicians to rule in the presence of rejection and
additionally predict a risk-read out for AR prior to any clinical
graft dysfunction. A strategy that combines both non-invasive tests
could therefore enable biopsy avoidance in a larger number of
patients than either test alone. The observed gene expression
patterns in this study challenge the current paradigm of classifying
certain rejection grades, such as Grade 1B, as ‘‘mild’’ and
therefore not requiring intensification of immunosuppressive
therapy. Further testing in larger patient numbers and prospective
clinical trials will be necessary to additionally validate this panel,
with the goal of developing a noninvasive and clinically relevant
test for diagnosis of cardiac allograft rejection.
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